![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 8, 6441-6446, February 25, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


¶
From the
Section of Cellular and Molecular Physiology and
Joslin Proteomics Core, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215
The most commonly detected polymorphism in human insulin receptor substrate-1 (IRS-1), a glycine to arginine change at codon 972 (G972R), is associated with an increased risk of Type 2 diabetes and insulin resistance. To determine the molecular mechanism by which this polymorphism may be linked to insulin resistance, we produced recombinant peptides comprising amino acid residues 9251008 from IRS-1 that contain either a glycine or arginine at codon 972 and the two nearby tyrosine phosphorylation consensus sites (EY941MLM and DY989MTM), which are known binding sites for the p85
regulatory subunit of phosphatidylinositol 3-kinase. The wild type peptide could be phosphorylated at these sites in vitro by purified insulin receptor. Introduction of the G972R polymorphism into the peptide reduced the amount of tyrosine phosphorylation by >60%. Pull-down experiments indicated that there was an association between the IRS-1-(9251008) peptide and the insulin receptor that was markedly enhanced by the presence of the G972R polymorphism. The use of additional overlapping fragments localized this interaction to domains between residues 950986 of IRS-1 and residues 9661271 of the insulin receptor, containing the tyrosine kinase domain of the receptor. In addition, the IRS-1-(9251008) G972R peptide acted as a competitive inhibitor of insulin receptor and insulin-like growth factor-1 receptor autophosphorylation. Taken together, these data indicate that the G972R naturally occurring polymorphism of IRS-1 not only reduces phosphorylation of the substrate but allows IRS-1 to act as an inhibitor of the insulin receptor kinase, producing global insulin resistance.
Received for publication, October 29, 2004
* This work was supported by National Institutes of Health Grant DK33201 (to C. R. K.) and by Joslin Diabetes and Endocrinology Research Center Grant DK34834 (to C. R. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Section of Cellular and Molecular Physiology, Joslin Diabetes Center, Harvard Medical School, One Joslin Place, Boston, MA 02215. Tel.: 617-732-2635; Fax: 617-732-2487; E-mail: c.ronald.kahn{at}joslin.harvard.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
O. Tschritter, H. Preissl, A. M. Hennige, M. Stumvoll, K. Porubska, R. Frost, H. Marx, B. Klosel, W. Lutzenberger, N. Birbaumer, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: A magnetoencephalographic study PNAS, August 8, 2006; 103(32): 12103 - 12108. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |